I-LOVE-IT2: Drug-eluting stents with a permanent polymer versus biodegradable in the same cobalt chromium platform

There is no strong evidence in the literature that the polymer type isolated (permanent or degradable) influences clinical outcomes after angioplasty and if the time of double anti-aggregation should be different with the degradable polymer. This work, with non-inferiority design, aimed to compare the sirolimus-eluting biodegradable polymer stent (Tivoli) versus the permanent polymer sirolimus-eluting stent (Firebird 2). The primary end point was a composite of cardiac death, myocardial infarction related to the vessel and target vessel revascularization. 

2737 patients from 32 Chinese centers were randomized, demonstrating non-inferiority of the biodegradable polymer stent at 12 months with 6.3% events versus 6.1% of the permanent polymer stent. Comparing each component of the primary end point individually no significant differences were observed between the two devices. 


Bo Xu
2014-09-17

Original title: A Prospective, Randomized Trial of a Biodegradable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent Versus a Durable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent in Patients with Coronary Artery Disease.

More articles by this author

EVERBIO II: Bio-absorbable stent Absorb versus everolimus-eluting or biolimus stents

The new generation drug-eluting everolimus or biolimus stents have proved superior to the first generation. However, neo intimal proliferation and late thrombosis remains a...

EXCITE ISR: Excimer laser versus balloon angioplasty for stent restenosis of the superficial femoral

This multicenter, prospective, randomized trial compared the Excimer laser atherectomy (Excimer Laser Atherectomy = ELA, Spectranetics, Inc.) with a balloon angioplasty in patients with...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Prehospital heparin in STEMI: A safe strategy associated with improved early reperfusion

Early reperfusion remains the main prognostic determinant in patients with ST-segment elevation myocardial infarction (STEMI). Although primary percutaneous coronary intervention (PCI) is the treatment...

SAPIEN 3 TAVI Durability: Ten-Year Follow-Up in Intermediate-Risk Patients

The durability of transcatheter bioprosthetic valves used in TAVI remains one of the key unanswered questions as indications continue to expand toward patients with...

Aneurysm Sac Regression Predicts Better Clinical Outcomes After EVAR?

Aneurysm sac regression following endovascular abdominal aortic aneurysm repair (EVAR) has been proposed as a marker of favorable remodeling and effective aneurysm exclusion. However,...